Investor Presentation
Accredited Investors Only
Market Opportunity
Why does this matter?
Every year, there are approximately 1.25 billion ambulatory care visits in the United States, including those at primary care offices, hospital emergency rooms, outpatient clinics and other settings. We estimate that approximately 417 million, or 33% of these visits, could be treated through telehealth. Based on the number of estimated telehealth visits and the average cost per telehealth visit, we estimate our annual market opportunity to be approximately $17 billion dollars.
Meet the Team
Joseph Barr, PhD.
Chief Technology Officer
University of New Mexico, Albuquerque, NM PhD, Mathematics, Florida State University MS, Mathematics, University of Haifa BA, Mathematics & Statistics
Don Stephenson
Chief Software Architect
Keith Burgess, PhD.
Principal Scientist
M.S & PhD. in Electrical Engineering, University of Wisconsin-Madison Post-Doctoral Fellow, University of Wisconsin-Madison B.S. in Physics, University of Chicago
Daniela D’Auria, PhD.
Scientist
PhD. in Computer Science and Automation Engineering, University of Naples Federico II Engineering Degree and Biomedical Engineering Degree
Vagelis Hristidis, PhD.
Scientist
PhD. in Computer Science, University of California, San Diego.
Fabio Persia, PhD.
Scientist
PhD. in Computer Science and Engineering, University of Naples Federico II Masters Degree in Computer Engineering, University of Naples Federico II Bachelor Degree in Computer Engineering University of Naples Federico II
Reasons to Invest
- The global digital health market is expected to rise from $84 billion in 2018, to $504.4 billion by 2025.
- Digital healthcare services will bring access, affordability and efficiency to healthcare, on a scale unseen by previous generations.
- We are developing a highly scalable platform that will be capable of serving to over 100 million EntelMed Members worldwide.
- Our core platform will provide member support and response time for over 50,000 visits per day.
- Our platform will be developed to accommodate the seamless and quick introduction of new services.
- Our clients will consist of employers, including Fortune 500 companies, health plans and health systems and other entities. We believe there are approximately 75 million potential members in these existing clients alone.
The Problem
The current healthcare system is facing massive challenges that require modern solutions. Of the many challenges, access to healthcare is among the most serious. “About 44 million people in the US have no health insurance, and another 38 million have inadequate health insurance.”-PBS. This means 22% of the US population is underserved by the current healthcare system.
This problem is not unique to the US, the World Bank and WHO estimate “half the world’s population lack access to essential healthcare services and 100 million people have been pushed into extreme poverty because of healthcare expense.” Expense is a major driver in healthcare inequality, but mobility, distance from facilities, and facility inefficiencies also contribute to the failing system.
EntelMed’s objective is to build a platform that substantially lowers the barriers to entry, allowing for instant access to healthcare services and on-demand health programs. By increasing access and efficiency, we believe EntelMed will disrupt the current healthcare marketplace and bring health and wellness services to millions.
Growth of Digital Healthcare
CAGR (2019-20205): 29.6%
The digital healthcare market is experiencing a meteoric rise.
Industry Data
Market Opportunity
The US providing $20 billion to hospitals and doctors to support their installation of EHRs is expected to fuel business growth.
Electronic health records business is estimated reach $139.4 billion by 2025.
Ability of these systems to exchange health information electronically to provide improved patient care are major factors contributing towards business growth.
These systems enable providers to more effectively diagnose patients, reduce medical errors, and provide safer care to patients with better communication. This will further escalate segmental growth over the coming years.
“Clinically-proven evidence was cited as critical for adoption by both payors and policymakers interviewed.”
According to a new study from the Consumer Technology Association (CTA), 68% of physicians strongly intend to use remote patient monitoring technology in the future.
Over half (52%) of consumers indicate they would use a connected health device as part of their treatment if a doctor made the recommendation, showing physicians as a strong driver for the use of technology in managing conditions.
56%
of consumers would be happy to share health data with their doctor in order to get more accurate diagnosis and treatment solutions.
31%
would be influenced by pharmacist recommendations or by a health insurance company.
>50%
of health care professionals believe that funding for health technology is the responsibility of the technology industry and manufacturers developing solutions.
Almost
1 in 2
Health care professionals believe technology has made health and fitness more accessible to their patients and agree that patients are happy to share this data with them.
EntelMed’s Solution
EntelMed is building a platform to
deliver virtual care technology solutions.
Physicians, clinics and hospitals will use the EntelMed IQ technology to remotely monitor patients using biosensors, electronic monitoring devices, electronic information and telecommunication technology to support long distance patient and clinical contact, care, advice, reminders, education, intervention, patient monitoring, and remote admissions.
Software
Layered software modules to enable a broad range of scheduled and unscheduled clinical workflows.
Devices
Purpose-built software and devices to ensure reliable connections across the entire care continuum.
Clinical Solutions
Elements of the EntelMed Platform are combined to deliver a wide range of clinical use case solutions.
The EntelMed remote patient monitoring (RPM) and telehealth platform will combine:
Connected sensors with smart phones, sensors and devices
Artificial Intelligence
Software and Services
Online Dashboard and Mobile Apps
Data Analytics
Electronic Health Records
Motivational and Social Tools
Personalized Insights
Virtual Coaching Thorough Customized Healthcare Plans
EntelMed’s Platform
Technology enables
virtualization of care.
The EntelMed IQ platform will integrate with the payor community to enable us to uniquely provide real time eligibility checking, real time member financial liability calculations, and clinical data exchange.
Our platforms APIs power external connectivity and deep integration with a wide range of payors, third party applications and other interfaces which will uniquely position us to be a central partner meeting the unique needs of the rapidly emerging, technology powered healthcare industry.
In addition, EntelMed IQ will incorporate core functionality required to offer a full spectrum of vital healthcare services on a single system. Our platform features predictive modeling, automated complex routing, queuing and scheduling.
Capabilities
Customizable
Software Modules
Products & Services
Platform
Devices
Operating System
Software
Physician Services
Patient Profile
EntelMed Patient Profile and Capabilities
- Diabetes
- Heart Disease
- Dermatology
- Dementia
- Chronic pulmonary disease (COPD)
- Patients diagnosed with chronic illness.
- Patients with mobility issues.
- Post surgery patients
- Stroke and rehabilitation
- Substance abuse
- Infertility
- Weight gain/loss
- Cognitive: stress, anxiety, memory decline, traumatic brain injury
- Pain: Chronic, acute, pain distraction, pain syndromes, hot flashes, and night sweats
- Motor: neck pain, shoulder pain, spinal cord injuries, and neurological disorders
- Elderly patients
- Neonates
Patient Benefits
2 in 3 Physicians plan to use remote patient monitoring in the future.
49%
Improved patient outcomes.
44%
Improved compliance rates.
42%
Patients taking more ownership of their health.
43%
Patients benefit from detailed information on personalized health.
42%
Faster access to health care services
Distribution
Channel Partners
B2B Direct Channel
DTC Channel
Health Plans
US Health Plan Clients
Global Insurers & Financial Services
Global Insurers & Financial Services Firms
Employers
All Sizes and Industries, Fortune 500
Hospitals & Health Systems
Care Locations, Hospitals, IDNs
Direct to Consumers
Leading Mental Health Platform
We are planning to open twenty offices globally.
Service patients from more than 50 countries.
Deliver care in more than 20 languages.
Growth Strategy
- Develop extensive client relationships
- Expand capabilities through strategic acquisitions
- Focus on innovation by leveraging our information, advanced analytics, transformative technology and domain experience
- Expand the penetration of our offerings to the broader healthcare marketplace.
Clinical Services
- Virtual Primary Care
- Expanded Specialty Care
- Pediatric Mental Health
- Remote Patient Monitoring
- Expanded Chronic Condition
- Management
- Second Opinions
New Payment Models
- Medicare/Medicaid FFS
- Value-base Care
- Gain Sharing
- Risk Sharing
- IQW-O VWDWH Sponsored Healthcare
- Direct to Consumer Payment System
- Second Opinions
New Care Settings
- Home-Based Care
- Post-Acute
- Primary Care/Specialty practice
- Retail Clinic
- Worksite
Clients and Members
Our clients will consist of employers, including Fortune 500 companies, health plans and health systems and other entities. Our goal is to reach 20 million members globally.
1. Virtual healthcare services on a business-to-business basis to thousands of Clients spanning the global healthcare distribution landscape and provide services to consumes directly and through channel partners
2. Our behavioral health business will serve individuals in the direct-to-consumer market and through business partnerships with other trusted brands.
3. EntelMed health employers, health plans, hospitals and health systems, and insurance and financial services companies. (Clients)
4. Employers, such as banks and financial institutions, industrial corporations, telecommunication companies, and other large employers.
5. Health plans, such as major insurance companies. Our strategy is to pursue and include health plans such as Blue Shield, Blue Cross, Aetna, CIGNA, United Health, and other insurance companies.
6. Self-insured Clients.
We believe there are approximately 75 million potential Members within these existing Clients.
Growth Strategy
Our business model is to generate revenue on a contractually recurring, subscription access fee basis, typically on a per-member-per-month (PMPM) basis, and in certain contracts, on a per subscriber basis.
Our subscription access fee will comprise the majority of our revenue and therefore provide us with significant revenue visibility. We will also generate additional revenue on a per-visit basis through certain Clients with visit fee only (VFO) arrangements.
Our subscription access fee will be paid by our Clients on behalf of their employees, dependents, policy holders, card holders, beneficiaries or, as is the case with certain subscribers, fees are paid by our Members themselves. General medical and other specialty visits fees are paid by Clients and/or Members.
For certain Clients, we expect to also earn visit fees or per-case fees in combination with subscription access fees.
Subscription access fee services is expected to be the most appealing for our Clients.
Offering Summary
Company
EntelMed, Inc.
Corporate Address
9844 Research Dr., Suite 200, Irvine, CA 92618
Offering
500,000 shares of the Company’s Series A Convertible Preferred Stock.
Price
$2.00 per Share. Shares will be offered at $2.00 per share until 500,000 shares have been sold.
Size of Offering
$1,000,000 Maximum Offering
Minimum Investment
Minimum purchase of 50,000 Shares at $2.00 per share purchase price ($100,000)
Who can Invest?
This Offering is only being made to investors who are accredited investors (a net worth in excess of $1,000,000 excluding the value of primary residence or (2) an annual income of at least $200,000 in each of the two most recent years.
We are offering the Shares pursuant to an exemption from the registration requirements of the Securities Act provided by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D thereunder (“Regulation D”). Each purchaser of the Shares in the Offering must qualify as an “accredited investor,” as defined in Rule 501(a) of Regulation D, and must verify their status as an accredited investor in accordance with Rule 506 before investing.
Important Information:
Certain information contained in this website constitutes “forward-looking statements,” which can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “target,” “project,” “estimate,” “intend,” “continue” or “believe,” or the negatives thereof or other variations thereon or comparable terminology. A private investment investment involves risk. There can be no assurance that the Company will be successful in developing, selling or generating revenue from its technology. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration. The Shares are speculative and illiquid securities involving substantial risk of loss. The Shares are not listed on any securities exchange, and it is not anticipated that a secondary market for the Shares will develop. The Shares are subject to substantial restrictions on transferability and resale and may not be transferred or resold except as permitted under the Securities Act and applicable state securities laws, pursuant to registration or exemption therefrom. The Shares are appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment and for whom an investment in the Company does not constitute a complete investment program.